Questions?

Organ-on-chips (OOCs) are an upcoming class of therapeutic testing models that have garnered significant attention of pharmaceutical companies, and academic / research institutions across the globe.

According to RootsAnalysis the global organ on a chip market size, valued at USD 78 million in 2024, is projected to reach USD 100 million in 2025 and USD 944 million by 2035, representing a CAGR of 25.2% during the forecast period.

More than 70 organ-on-a-chip technologies and models have been launched / approved or are currently under development; notably, the market landscape features the presence of both established players and new entrants. The global organs on chips market size is estimated to be USD 77 million in 2024 and is projected to reach USD 944 million by 2035.The market is anticipated to grow at a CAGR of 25.6%, during the forecast period till 2035.
During our research, we were able to identify more than 25 prominent players that offer organ-on-a-chip technologies and models. It is worth mentioning that more than 55% of the technologies and model providers are headquartered in Europe. This can be attributed to the fact that the region has shown significant growth in the domain supported by the increasing collaborations between companies and government institutes along with the increasing research efforts and fundings.

97% of the technologies and models offer drug discovery / toxicity testing as their area of application. It is also worth mentioning that liver based models emerged as the most prominent single organ based model (33%), followed by lung based models (29%).

Further, considering the active engagement of industry players in this domain, the market for organ-on-a-chip technologies and models is likely to grow in the foreseen future.

Presently, 25 players (established players as well as start-ups) claim to provide organ-on-a-chip and plates; more than 60% of these firms have been established post-2013

More than 20 prominent players that offer organ-on-chips and plates. It is worth mentioning that more than 55% of the chips and plate providers are headquartered in Europe, of these, most of the players are headquartered in France (29%). This can be attributed to the fact that significant investments in research combined with strategic collaborations between industry and non-industry players is accelerating biofabrication advancements, propelling the growth of the market.

94% of the chips and plates are made of polymer, of which, 50% of the products are made of polydimethylsiloxane (PDMS). This can be attributed to the fact that PDMS provides gas permeability, flexibility and transparency to the chip base, which makes it easy and cost efficient to manufacture chips and plates. Further, considering the active engagement of industry players in this domain, the market for organ-on-chips and plates is likely to grow in the foreseen future.

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html